Clinomics Inc.

Equities

A352770

KR7352770002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 01/07/2024 BST			5-day change	1st Jan Change
1,487 ^KRW	-3.44%		-15.75%	-42.03%

05-17	Clinomics Inc. announced that it has received KRW 4 billion in funding	CI
05-14	Clinomics Inc. announced that it expects to receive KRW 4 billion in funding	CI

Clinomics Inc. announced that it has received KRW 32.600017466 billion in funding from Cdbio Co., Ltd., Daon Engineering Co., Ltd, Baro Savings Bank, The Korea Securities Finance Corporation

May 07, 2024

On May 8, 2024, Clinomics Inc. closed the transaction. The company announced that it has issued 3% Series 3 Bearer-Type Non-Guaranteed Private Placement Convertible Bond due May 8, 2027 for the gross proceeds of KRW 12,000,000,000 in its second tranche.

Latest news about Clinomics Inc.

Clinomics Inc. announced that it has received KRW 4 billion in funding	05-16	CI
Clinomics Inc. announced that it expects to receive KRW 4 billion in funding	05-13	CI
Clinomics Inc. announced that it has received KRW 32.600017466 billion in funding from Cdbio Co., Ltd., Daon Engineering Co., Ltd, Baro Savings Bank, The Korea Securities Finance Corporation	05-07	CI
Clinomics Inc. agreed to acquire New Oriental Hotel Co., Ltd from Daon Engineering Co., Ltd and Gi-dong Song for KRW 18.5 billion.	05-02	CI
Clinomics Inc. announced that it expects to receive KRW 15 billion in funding from Busan Equity Partners Co., Ltd.	12-14	CI
Tranche Update on Clinomics Inc.'s Equity Buyback Plan announced on August 30, 2023.	30/08/23	CI
Clinomics Inc. announces an Equity Buyback for 124,764 shares.	30/08/23	CI
Clinomics Inc.'s Equity Buyback announced on August 30, 2023, has closed with 124,764 shares, representing 0.61% for KRW 299.43 million.	29/08/23	CI
Clinomics Inc. authorizes a Buyback Plan.	29/08/23	CI
Clinomics to Raise 44.6 Billion Won via Shares Issuance	22/05/23	MT
Clinomics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23	CI
Clinomics Inc. announced that it expects to receive KRW 2.3 billion in funding	20/02/23	CI
Clinomics Inc. announced that it has received KRW 2.99999694 billion in funding	15/12/22	CI
Clinomics Inc. announced that it expects to receive KRW 2.99999694 billion in funding	30/11/22	CI
Clinomics Inc.(KOSDAQ:A352770) dropped from S&P Global BMI Index	19/09/22	CI
Clinomics Inc. announced that it has received KRW 30 billion in funding	06/07/21	CI
Clinomics Inc. announced that it expects to receive KRW 30 billion in funding	01/07/21	CI
Clinomics Inc.(KOSDAQ:A352770) added to S&P Global BMI Index	21/06/21	CI
Clinomics Inc. has completed an IPO in the amount of KRW 27.41529 billion.	26/11/20	CI
Clinomics Inc. has filed an IPO.	10/07/20	CI

Chart Clinomics Inc.

Duration

Period

More charts

Company Profile

Clinomics Inc is a Korea-based company engaged in the development of genome diagnostic tests and liquid biopsies. The Company's main businesses are multi-omics-based service business and liquid biopsy-based cancer diagnosis and screening business. The multi-omics-based service business provides products and services that predict physical characteristics and diseases based on genome diagnosis and tests, and provides early diagnosis services for major diseases such as cancer based on multi-omics. The liquid biopsy-based cancer diagnosis and screening business sells medical devices that diagnose patients by extracting blood cells and deoxyribonucleic acid (DNA), and diagnostic and monitoring kits for cancer mutations in patients. It is also develops products that diagnoses cancer early with blood.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CLINOMICS INC.	-42.03%	42.79M
MODERNA, INC.	+17.72%	44.44B
IQVIA HOLDINGS INC.	-10.33%	37.99B
LONZA GROUP AG	+37.55%	37.75B
ALNYLAM PHARMACEUTICALS, INC.	+29.36%	30.78B
CELLTRION, INC.	-8.44%	27.38B
ICON PUBLIC LIMITED COMPANY	+12.45%	26.17B
UNITED THERAPEUTICS CORPORATION	+44.19%	14.15B
MEDPACE HOLDINGS, INC.	+31.93%	12.59B
BIO-TECHNE CORPORATION	-7.67%	11.28B

Other Biotechnology & Medical Research